RxDoctor Payments Data

John Stanhope, DO

Family Medicine · New Braunfels, TXNPI 1740331016

Payments from drug & device makers

$1,752in general payments, 2019–2025

Across 62 payments — averaging $28.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$356
  • Abbott$294
  • Novo Nordisk$237
  • Aerin Medical Inc.$135
  • Otsuka America Pharmaceutical, Inc.$110
  • Amarin Pharma, Inc.$108
  • plus $512 from 18 others

What the payments were for

  • Food & beverage$1,752100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,752 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$47,421
Medicare patients
211
Services billed
532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol61$65,281
OzempicSemaglutide57$59,816
JardianceEmpagliflozin28$40,150
JanuviaSitagliptin Phosphate20$29,438
EliquisApixaban32$28,013
TrulicityDulaglutide20$18,324
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,192
Breo ElliptaFluticasone/Vilanterol22$10,653
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$9,953
Tresiba Flextouch U-100Insulin Degludec12$5,873
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,727
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$5,118
Gabapentin228$4,747
Atorvastatin Calcium395$3,791
Albuterol Sulfate HfaAlbuterol Sulfate94$2,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$41$65,28161 claims
Novo NordiskOzempic$237$59,81657 claims
Boehringer IngelheimJardiance$15$40,15028 claims
Lilly USA, LLCTrulicity$57$18,32420 claims
AbbVieArmour Thyroid$36$96711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in New Braunfels

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →